Millennium | Clinicians | Oncology | VELCADE | Dosing Modifications Guidlines

	MANTLE CELL LYMPHOMA



	MECHANISM
	DISEASE BACKGROUND
	PINNACLE TRIAL DESIGN AND RESULTS
	SAFETY PROFILE
	DOSING SCHEDULE
	DOSE MODIFICATION GUIDLINES
	HANDLING AND ADMINISTRATION
	IMPORTANT SAFETY INFORMATION
	REIMBURSEMENT
	ADDITIONAL INFORMATION
	REFERENCES

RECOMMENDED DOSE MODIFICATION FOR VELCADE

DOSE MODIFICATION TO MANAGE ADVERSE EVENTS

In the PINNACLE trial, less than 8% of patients required dose reductions

VELCADE therapy should be withheld at the onset of any grade 3 non-hematological or grade 4 hematological toxicities excluding neuropathy

–	Once the symptoms of the toxicity have resolved, VELCADE therapy may be reinitiated at a 25% reduced dose

For neuropathic pain and/or peripheral sensory or motor neuropathy related to VELCADE

† National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0. December 2003.

The long-term outcome of peripheral neuropathy has not been studied in MCL

Please click here to view additional important safety information.

For full Prescribing Information click here. (pdf) (74KB)

For further information about VELCADE^® (bortezomib) for Injection, call 1-866-VELCADE (U.S. clinicians only).